Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Hospira, Inc. Snapshot 7
Hospira, Inc. Overview 7
Key Information 7
Key Facts 7
Hospira, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Hospira, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Hospira, Inc. – Pipeline Products Glance 12
Hospira, Inc. – Late Stage Pipeline 12
Registration Filed Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Hospira, Inc. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Hospira, Inc. – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Hospira, Inc. – Drug Profiles 17
Biosimilar Erythropoietin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Dyloject 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
mAb 1 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
mAb 2 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Nivestim 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Pegfilgrastim Biosimilar 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
POSIDUR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Research and Development Brief 25
Licensing and Collaboration 25
Phase II - Trial Details 25
Phase III - Trial Details 26
Hospira, Inc. – Pipeline Analysis 27
Hospira, Inc. – Pipeline Products by Therapeutic Class 27
Hospira, Inc. – Pipeline Products by Route of Administration 29
Hospira, Inc. – Pipeline Products By Mechanism of Action 30
Hospira, Inc. – Recent Pipeline Updates 31
Hospira, Inc. - Dormant Projects 32
Hospira, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
Dexmedetomidine 33
E21R 33
Hospira, Inc. – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Hospira, Inc. - Key Manufacturing Facilities 38
Hospira, Inc., Recent Developments 39
Hospira, Inc.- Press Release 39
Apr 17, 2012: Hospira Initiates Nationwide Voluntary Recall Of One Lot Of Morphine Sulfate Injection, USP 4mg/ml 39
Jan 09, 2012: Hospira Initiates US Phase III Biosimilar Erythropoietin Clinical Program 39
Oct 26, 2009: Hospira completes decentralized procedure for generic Docetaxel - full launch expected end 2010. 40
Dec 02, 2009: Javelin Pharmaceuticals Files New Drug Application Of Dyloject With FDA For Management Of Acute Moderate-To-Severe Pain 40
Jun 29, 2009: Hospira Receives FDA Approval for Azithromycin for Injection 41
Feb 02, 2009: Hospira's Precedex Phase IV Study Published in the Journal of The American Medical Association 41
Financial Deals Landscape 43
Hospira, Inc., Deals Summary 43
Hospira, Inc., Pharmaceuticals & Healthcare, Deal Details 45
Asset Transactions 45
Hospira Completes Acquisition Of Injectable Pharma Business Of Orchid Chemicals & Pharma 45
Hospira Acquires Worldwide Rights To Filgrastim From PLIVA 48
Hospira Acquires EndoTool Business From MD Scientific 53
Hospira Acquires Clayton Manufacturing Facility From Fresenius Kabi 55
Mayne Pharma Acquires M.V.I. And Aquasol From AAIPharma 57
Partnerships 58
ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 58
ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 59
Hospira Enters Into An Agreement With Smiths Medical 60
Hospira Enters Into Agreement With University of Alabama at Birmingham 61
Hospira Enters Into Co-Marketing Agreement With Celltrion 62
StemCor Systems Enters Into An Agreement With Hospira 63
Altea Therapeutics Enters Into An Agreement With Hospira 64
Orexo Enters Into Co-Marketing Agreement With Hospira 65
Hospira Enters Into Joint Venture Agreement With Cadila Healthcare 66
Hospira Signs An Agreement With STADA 67
Hikma Pharma Signs An Agreement With Hospira 68
Cerner Enters Into An Agreement With Hospira 69
Hospira Enters Into An Agreement With ICU Medical 70
Hospira Signs An Agreement With Bridge Medical 71
Licensing Agreements 72
National Institutes Of Health Enters Into Licensing Agreement With TheraDoc 72
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 73
Hospira Enters Into Licensing Agreement With DURECT 74
ChemGenex Pharma Enters Into Licensing Agreement With Hospira 76
BioTime Amends Licensing Agreement With Hospira 77
Debt Offering 78
Hospira Completes Debt Offering Of Senior Notes Due 2040 For $500 Million 78
Hospira Completes Public Offering Of 6.4% Notes For $250 Million 80
Hospira Completes Public Offering Of Floating Rate Notes For $375 Million 82
Hospira Completes Public Offering Of 5.55% Notes For $500 Million 84
Hospira Completes Public Offering Of 6.05% Notes For $550 Million 86
Hospira Completes Public Offering Of 4.95% Senior Unsecured Notes For $300 Million 88
Hospira Completes Public Offering Of 5.9% Senior Unsecured Notes For $400 Million 89
Asset Transactions 90
SEDLine Acquires SEDLine Brain Function Monitoring Business From Hospira 90
Hospira Sells Contract Manufacturing Facility In Australia For $6.4 Million 91
ICU Medical Completes Acquisition Of Critical Care Product Line From Hospira 92
Barr Pharma Acquires Generic Products From Hospira 94
ICU Medical Acquires Salt Lake City Manufacturing Facility From Hospira 95
Acquisition 97
Hospira Completes Acquisition Of Javelin Pharma 97
Recipharm Acquires Wasserburger Arzneimittelwerk 100
Hospira Acquires TheraDoc 102
HalcyGen Acquires Mayne Pharma From Hospira 103
Hospira Acquires Sculptor Developmental Technologies 105
Hospira Acquires Mayne Pharma 106
Hospira Acquires BresaGen From Paragon Advisory 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 111
Disclaimer 111

List of Tables
List of Tables
Hospira, Inc., Key Information 7
Hospira, Inc., Key Facts 7
Hospira, Inc. – Pipeline by Indication, 2012 9
Hospira, Inc. – Pipeline by Stage of Development, 2012 10
Hospira, Inc. – Monotherapy Products in Pipeline, 2012 11
Hospira, Inc. – Filed, 2012 12
Hospira, Inc. – Phase III, 2012 13
Hospira, Inc. – Phase I, 2012 14
Hospira, Inc. – Pre-Clinical, 2012 15
Hospira, Inc. – Discovery, 2012 16
Hospira, Inc. – Pipeline By Therapeutic Class, 2012 28
Hospira, Inc. – Pipeline By Route of Administration, 2012 29
Hospira, Inc. – Pipeline Products By Mechanism of Action, 2012 30
Hospira, Inc. – Recent Pipeline Updates, 2012 31
Hospira, Inc. - Dormant Developmental Projects,2012 32
Hospira, Inc. - Discontinued Pipeline Products, 2012 33
Hospira, Inc., Other Locations 34
Hospira, Inc., Subsidiaries 35
Hospira, Inc., Key Manufacturing Facilities 38
Hospira, Inc., Deals Summary 43
Hospira Completes Acquisition Of Injectable Pharma Business Of Orchid Chemicals & Pharma 45
Hospira Acquires Worldwide Rights To Filgrastim From PLIVA 48
Hospira Acquires EndoTool Business From MD Scientific 53
Hospira Acquires Clayton Manufacturing Facility From Fresenius Kabi 55
Mayne Pharma Acquires M.V.I. And Aquasol From AAIPharma 57
ICU Medical Extends Distribution Agreement With Hospira For Infusion Sets 58
ICU Medical Extends Distribution Agreement With Hospira For CLAVE And Oncology Products 59
Hospira Enters Into An Agreement With Smiths Medical 60
Hospira Enters Into Agreement With University of Alabama at Birmingham 61
Hospira Enters Into Co-Marketing Agreement With Celltrion 62
StemCor Systems Enters Into An Agreement With Hospira 63
Altea Therapeutics Enters Into An Agreement With Hospira 64
Orexo Enters Into Co-Marketing Agreement With Hospira 65
Hospira Enters Into Joint Venture Agreement With Cadila Healthcare 66
Hospira Signs An Agreement With STADA 67
Hikma Pharma Signs An Agreement With Hospira 68
Cerner Enters Into An Agreement With Hospira 69
Hospira Enters Into An Agreement With ICU Medical 70
Hospira Signs An Agreement With Bridge Medical 71
National Institutes Of Health Enters Into Licensing Agreement With TheraDoc 72
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 73
Hospira Enters Into Licensing Agreement With DURECT 74
ChemGenex Pharma Enters Into Licensing Agreement With Hospira 76
BioTime Amends Licensing Agreement With Hospira 77
Hospira Completes Debt Offering Of Senior Notes Due 2040 For $500 Million 78
Hospira Completes Public Offering Of 6.4% Notes For $250 Million 80
Hospira Completes Public Offering Of Floating Rate Notes For $375 Million 82
Hospira Completes Public Offering Of 5.55% Notes For $500 Million 84
Hospira Completes Public Offering Of 6.05% Notes For $550 Million 86
Hospira Completes Public Offering Of 4.95% Senior Unsecured Notes For $300 Million 88
Hospira Completes Public Offering Of 5.9% Senior Unsecured Notes For $400 Million 89
SEDLine Acquires SEDLine Brain Function Monitoring Business From Hospira 90
Hospira Sells Contract Manufacturing Facility In Australia For $6.4 Million 91
ICU Medical Completes Acquisition Of Critical Care Product Line From Hospira 92
Barr Pharma Acquires Generic Products From Hospira 94
ICU Medical Acquires Salt Lake City Manufacturing Facility From Hospira 95
Hospira Completes Acquisition Of Javelin Pharma 97
Recipharm Acquires Wasserburger Arzneimittelwerk 100
Hospira Acquires TheraDoc 102
HalcyGen Acquires Mayne Pharma From Hospira 103
Hospira Acquires Sculptor Developmental Technologies 105
Hospira Acquires Mayne Pharma 106
Hospira Acquires BresaGen From Paragon Advisory 108

List of Figures
List of Figures
Hospira, Inc. – Pipeline by Indication, 2012 9
Hospira, Inc. – Pipeline by Stage of Development, 2012 10
Hospira, Inc. – Monotherapy Products in Pipeline, 2012 11
Hospira, Inc. – Pipeline By Therapeutic Class, 2012 27
Hospira, Inc. – Pipeline By Route of Administration, 2012 29
Hospira, Inc. - Pipeline Products By Mechanism of Action, 2012 30